REPROCELL has launched StemEdit, a comprehensive gene editing platform for iPSCs and newly engineered iPSC lines enabled by OpenCRISPR-1™, an AI-designed genome editing system. The platform integrates high-fidelity genome engineering with predictive off-target modelling, designed to support research, translational development and future clinical applications.
From Research to Clinic: Streamlined iPSC Gene Editing
StemEdit enables a seamless transition from research-grade to clinical-grade iPSC lines. AI-optimized guide RNAs and precision editing tools minimize off-target effects, while standardized parameters and validated workflows reduce iterative optimization, accelerating development and ensuring reproducible outcomes from translational research to clinical applications.
The platform generates precisely defined genotypes before scale-up to master cell bank (MCB) production and supports complex modifications, including large gene knock-ins, biallelic edits, and single or multiplex knockouts.
From the start, StemEdit offers flexibility: clients can use their own iPSC line, choose from REPROCELL’s available research or clinical-grade clones, or develop a custom iPSC line tailored to their therapeutic program.
Projects can be conducted at REPROCELL USA (Beltsville, Maryland) or at the REPROCELL Japan GMP Manufacturing Facility, providing geographic and regulatory flexibility as programs progress.
StemEdit provides reproducible, traceable gene editing across research and clinical iPSC workflows, with flexibility in both starting materials and project scope.
Streamlined Research and Clinical Work
REPROCELL’s StemEdit service supports projects from initial design through generation of fully validated edited clones, bridging the technical gaps between discovery research and clinical development.
New Hypoimmune iPSC Lines
REPROCELL has launched StemEdit ready-to-use hypoimmune iPSC lines, engineered with OpenCRISPR-1. These lines are derived from StemRNA™ Clinical iPSC Seed Clones, generated using our in-house non-integrating StemRNA reprogramming technology under GMP aligned principles.
The hypoimmune iPSC lines are designed for reduced immune recognition and intended for research use, with a defined path toward clinical applications.
REPROCELL currently provides StemEdit hiPSC B2M/CIITA double-knockouts (DKO) RPC-LLF-34-F3 cells, with additional single CIITA KO and B2M KO lines available as part of an expanding product portfolio of genome-edited iPSC products.
Off-the-shelf GMP iPSC MCBs, manufactured at our US facility in Maryland from the corresponding parental clinical line, are also available. These banks enable developers to initiate editing programs on a regulatory-aligned foundation.
By combining OpenCRISPR-1 (open-source), clinically validated iPSC starting materials, and established manufacturing infrastructure, REPROCELL positions StemEdit as a comprehensive solution for biotech and pharmaceutical cell therapy developers, bridging research innovation and clinical translation.
For additional information about REPROCELL’s StemEdit service or hypoimmune iPSC lines, please contact info-us@reprocell.com.